{"title":"Ghrelin system and GLP-1 as potential treatment targets for alcohol use disorder.","authors":"Elisabet Jerlhag","doi":"10.1016/bs.irn.2024.07.006","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.07.006","url":null,"abstract":"<p><p>Peptides of the gut-brain axis have gained recent attention as potential treatment targets for addiction. While the number of gut-brain peptides is vast, ghrelin and glucagon-like peptide-1 (GLP-1) have been suggested as important players. Ghrelin is traditionally considered an orexigenic peptide, but recent studies found that it increases alcohol intake in rodents and craving for alcohol in humans. Additionally, suppression of the ghrelin receptor attenuates alcohol-related responses in animal models reflecting alcohol use disorder (AUD). For instance, a lower alcohol intake, suppressed motivation to consume alcohol, and attenuated reward from alcohol is observed after ghrelin receptor antagonism treatment. On a similar note, a partial ghrelin receptor agonist prevents hangover symptoms in humans. When it comes to the anorexigenic peptide GLP-1, agonists of its receptor are approved to treat diabetes type 2 and obesity. Extensive preclinical studies have revealed that these GLP-1 receptor agonists reduce alcohol intake, suppress the motivation to consume alcohol, and prevent relapse drink, with effects tentatively associated with a reduced alcohol-induced reward. These preclinical findings have to some extent been varied in humans, as GLP-1 receptor agonists decrease alcohol intake in overweight patients with AUD. Furthermore, genetic variations in either the genes encoding for pre-pro-ghrelin, GHSR, GLP-1, or its receptor, are associated with AUD and heavy alcohol drinking. While central mechanisms appear to modulate the ability of either ghrelin or GLP-1 to regulate alcohol-related responses the exact mechanisms have not been defined. Taken together these preclinical and clinical data imply that gut-brain peptides participate in the addiction process and should be considered as potential targets for AUD treatment.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"178 ","pages":"401-432"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cristiane Aparecida Favoretto, Natalia Bonetti Bertagna, Tarciso Tadeu Miguel, Isabel M H Quadros
{"title":"The CRF/Urocortin systems as therapeutic targets for alcohol use disorders.","authors":"Cristiane Aparecida Favoretto, Natalia Bonetti Bertagna, Tarciso Tadeu Miguel, Isabel M H Quadros","doi":"10.1016/bs.irn.2024.08.002","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.08.002","url":null,"abstract":"<p><p>Development and maintenance of alcohol use disorders have been proposed to recruit critical mechanisms involving Corticotropin Releasing Factor and Urocortins (CRF/Ucns). The CRF/Ucns system is comprised of a family of peptides (CRF, Ucn 1, Ucn 2, Ucn 3) which act upon two receptor subtypes, CRFR1 and CRFR2, each with different affinity profiles to the endogenous peptides and differential brain distribution. Activity of CRF/Ucn system is further modulated by CRF binding protein (CRF-BP), which regulates availability of CRF and Ucns to exert their actions. Extensive evidence in preclinical models support the involvement of CRF/Ucn targets in escalated alcohol drinking, as well as point to changes in CRF/Ucn brain function as a result of chronic alcohol exposure and/or withdrawal. It highlights the role of CRF and CRFR1-mediated signaling in conditions of excessive alcohol taking and seeking, including during various stages of withdrawal and relapse to alcohol. Besides its role in the hypothalamic-pituitary-adrenal (HPA) axis, the importance of extra-hypothalamic CRF pathways, especially in the extended amygdala, in the neurobiology of alcohol abuse and dependence is emphasized. Emerging roles for other targets of the CRF/Ucn system, such as CRF2 receptors, CRF-BP and Ucns in escalated alcohol drinking is also discussed. Finally, the limited translational value of CRF/Ucn interventions in stress-related and alcohol use disorders is discussed. So far, CRFR1 antagonists have shown little or no efficacy in human clinical trials, although a range of unexplored conditions and possibilities remain to be explored.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"178 ","pages":"97-152"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lucia Batzu, Aleksandra Podlewska, Lucy Gibson, K Ray Chaudhuri, Dag Aarsland
{"title":"A general clinical overview of the non-motor symptoms in Parkinson's disease: Neuropsychiatric symptoms.","authors":"Lucia Batzu, Aleksandra Podlewska, Lucy Gibson, K Ray Chaudhuri, Dag Aarsland","doi":"10.1016/bs.irn.2023.11.001","DOIUrl":"10.1016/bs.irn.2023.11.001","url":null,"abstract":"<p><p>The heterogeneity of non-motor features observed in people with Parkinson's disease (PD) is often dominated by one or more symptoms belonging to the neuropsychiatric spectrum, such as cognitive impairment, psychosis, depression, anxiety, and apathy. Due to their high prevalence in people with PD (PwP) and their occurrence in every stage of the disease, from the prodromal to the advanced stage, it is not surprising that PD can be conceptualised as a complex neuropsychiatric disorder. Despite progress in understanding the pathophysiological mechanisms underlying the neuropsychiatric signs and symptoms in PD, and better identification and diagnosis of these symptoms, effective treatments are still a major unmet need. The impact of these symptoms on the quality of life of PwP and caregivers, as well as their contribution to the overall non-motor symptom burden can be greater than that of motor symptoms and require a personalised, holistic approach. In this chapter, we provide a general clinical overview of the major neuropsychiatric symptoms of PD.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"174 ","pages":"59-97"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139716763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mubasher A Qamar, Phoebe Tall, Daniel van Wamelen, Yi Min Wan, Katarina Rukavina, Anna Fieldwalker, Donna Matthew, Valentina Leta, Kirsty Bannister, K Ray Chaudhuri
{"title":"Setting the clinical context to non-motor symptoms reflected by Park-pain, Park-sleep, and Park-autonomic subtypes of Parkinson's disease.","authors":"Mubasher A Qamar, Phoebe Tall, Daniel van Wamelen, Yi Min Wan, Katarina Rukavina, Anna Fieldwalker, Donna Matthew, Valentina Leta, Kirsty Bannister, K Ray Chaudhuri","doi":"10.1016/bs.irn.2023.08.012","DOIUrl":"10.1016/bs.irn.2023.08.012","url":null,"abstract":"<p><p>Non-motor symptoms (NMS) of Parkinson's disease (PD) are well described in both clinical practice and the literature, enabling their management and enhancing our understanding of PD. NMS can dominate the clinical pictures and NMS subtypes have recently been proposed, initially based on clinical observations, and later confirmed in data driven analyses of large datasets and in biomarker-based studies. In this chapter, we provide an update on what is known about three common subtypes of NMS in PD. The pain (Park-pain), sleep dysfunction (Park-sleep), and autonomic dysfunction (Park-autonomic), providing an overview of their individual classification, clinical manifestation, pathophysiology, diagnosis, and potential treatments.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"174 ","pages":"1-58"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139716769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rúbia Maria Weffort de Oliveira, Nathalia Akemi Kohara, Humberto Milani
{"title":"Cannabidiol in experimental cerebral ischemia.","authors":"Rúbia Maria Weffort de Oliveira, Nathalia Akemi Kohara, Humberto Milani","doi":"10.1016/bs.irn.2024.04.012","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.04.012","url":null,"abstract":"<p><p>The absence of blood flow in cerebral ischemic conditions triggers a multitude of intricate pathophysiological mechanisms, including excitotoxicity, oxidative stress, neuroinflammation, disruption of the blood-brain barrier and white matter disarrangement. Despite numerous experimental studies conducted in preclinical settings, existing treatments for cerebral ischemia (CI), such as mechanical and pharmacological therapies, remain constrained and often entail significant side effects. Therefore, there is an imperative to explore innovative strategies for addressing CI outcomes. Cannabidiol (CBD), the most abundant non-psychotomimetic compound derived from Cannabis sativa, is a pleiotropic substance that interacts with diverse molecular targets and has the potential to influence various pathophysiological processes, thereby contributing to enhanced outcomes in CI. This chapter provides a comprehensive overview of the primary effects of CBD in in vitro and diverse animal models of CI and delves into some of its plausible mechanisms of neuroprotection.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"177 ","pages":"95-120"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141728483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jan Rosner, Prasad Shirvalkar, Daniel Ciampi de Andrade
{"title":"Neuropathic pain - A clinical primer.","authors":"Jan Rosner, Prasad Shirvalkar, Daniel Ciampi de Andrade","doi":"10.1016/bs.irn.2024.10.014","DOIUrl":"10.1016/bs.irn.2024.10.014","url":null,"abstract":"<p><p>Neuropathic pain is used both as a mechanistic descriptor and a classification category of pain caused by a lesion or disease of the somatosensory nervous system and encompasses a vast array of possible diagnoses. The identification of neuropathic pain and diagnosis of specific syndromes relies on a detailed patient history. Standardized pain questionnaires can capture the patient`s symptoms, while the anatomical distribution of pain is often documented using pain drawings. Following this, a thorough clinical neurological examination is conducted to identify distinct sensory abnormalities, specifically sensory deficits and signs of increased sensitivity such as allodynia and hyperalgesia, within the pain-affected areas. Regardless of whether the lesion or disease is in the peripheral or central somatosensory nervous system, the presence of clinically overt sensory abnormalities is a key feature, distinguishing neuropathic pain from other types of pain, such as nociceptive pain, which likely coexist in neurological disorders. Extensive sensory deficits, as seen in certain stroke syndromes or following spinal cord injuries, may increase the likelihood of concomitant non-neuropathic pain within the same area of sensory loss. For this reason, differential diagnosis is essential when assessing patients with suspected neuropathic pain. Further diagnostic tests, including imaging or specific neurophysiological methods that assess nociceptive pathways, can provide objective evidence of a lesion or disease within the somatosensory nervous system. However, the causality between the lesion and the presence of neuropathic pain cannot be established definitively and always requires clinical judgment and interpretation within the broader context of the neurological disorder.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"179 ","pages":"41-65"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A Leslie Morrow, Minna H McFarland, Todd K O'Buckley, Donita L Robinson
{"title":"Emerging evidence for pregnane steroid therapeutics for alcohol use disorders.","authors":"A Leslie Morrow, Minna H McFarland, Todd K O'Buckley, Donita L Robinson","doi":"10.1016/bs.irn.2024.07.004","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.07.004","url":null,"abstract":"<p><p>Many lines of research have suggested that the neuroactive pregnane steroids, including pregnenolone, progesterone, and allopregnanolone ([3α,5α]-3-hydroxypregnan-20-one, 3α,5α-THP), have therapeutic potential for treatment of alcohol use disorders (AUDs). In this chapter, we systematically address the preclinical and clinical evidence that supports this approach for AUD treatment, describe the underlying neurobiology of AUDs that are targeted by these treatments, and delineate how pregnane steroids may address various components of the disease. This review updates the theoretical framework for understanding how endogenous steroids that modulate the effects of alcohol, stress, excitatory/inhibitory and dopamine transmission, and the innate immune system appear to play a key role in the prevention and mitigation of AUDs. We further discuss newly discovered limitations of pregnane steroid therapies as well as the challenges that are inherent to development of endogenous compounds for therapeutics. We argue that overcoming these challenges presents the opportunity to help millions who suffer from AUDs across the world.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"178 ","pages":"59-96"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Historical perspective on the therapeutic potential of cannabidiol.","authors":"Francisco Silveira Guimarães","doi":"10.1016/bs.irn.2024.03.008","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.03.008","url":null,"abstract":"<p><p>Cannabidiol (CBD) is one of over 200 cannabinoids present in the Cannabis plant. Unlike the plant's primary cannabinoid, delta-9-tetrahydrocannabinol (THC), CBD does not produce psychotomimetic effects nor induce dependence. Initially considered an inactive cannabinoid, interest in its pharmacological properties and therapeutic potential has grown exponentially over the last 20 years. Currently employed as a medication for certain epileptic syndromes, numerous pre-clinical and clinical studies support its potential use in various other disorders. In this chapter, we provide a brief historical overview of how this compound evolved from an \"inactive substance\" to a multifunctional clinical agent. Additionally, we discuss the current challenges in researching its potential therapeutic effects.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"177 ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141728485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Phosphatidylethanol (B-PEth) and other direct and indirect biomarkers of alcohol consumption.","authors":"Andrea de Bejczy","doi":"10.1016/bs.irn.2024.03.004","DOIUrl":"10.1016/bs.irn.2024.03.004","url":null,"abstract":"<p><p>When identifying, preventing and treating alcohol use disorder, a correct estimation of alcohol intake is essential. An objective marker is preferred as self-reported alcohol intake suffers from bias, and the use of alcohol biomarkers is increasing globally. An easy-to-use blood biomarker to correctly assess alcohol consumption is an invaluable asset in alcohol treatment strategies, as well as in alcohol research studies. The specific, cumulative, biomarker phosphatidylethanol, mirroring the past two weeks of consumption, has shown superiority over traditional biomarkers and is an attractive choice of proxy for alcohol intake.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"175 ","pages":"313-344"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140330370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Advances in symptom management and in monitoring disease progression in motor neuron disease.","authors":"Esther Hobson, Christopher McDermott","doi":"10.1016/bs.irn.2024.04.004","DOIUrl":"10.1016/bs.irn.2024.04.004","url":null,"abstract":"<p><p>The aim of supportive management of motor neuron disease is to improve survival, promote good quality of life and patient independence and autonomy whilst preparing for future progression and the end of life. Multidisciplinary specialist care aims to address the multifaceted and interacting biopsychosocial problems associated with motor neuron disease that leads to proven benefits in both survival and quality of life. This chapter will explore principles, structure and details of treatment options, and make recommendations for practice and for future research.</p>","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"176 ","pages":"119-169"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141159327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}